Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
NCT ID: NCT01661361
Last Updated: 2012-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
15 participants
OBSERVATIONAL
2012-09-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated yielding residual vancomycin levels of less than 0.5 mg/L.
In this study, the investigators want to evaluate this flushing technique in vivo in 15 patients admitted with catheter-related infection and treated with systemic vancomycin and vancomycin antibiotic lock.
The purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained via port sampling.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vancomycin cohort
blood levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood levels
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having central venous port device,
* treated with systemic vancomycin in combination with vancomycin antibiotic lock
Exclusion Criteria
* children,
* patients with 'do not resuscitate' (DNR) code
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Isabelle Spriet
PharmD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabel Spriet, PharmD PhD
Role: PRINCIPAL_INVESTIGATOR
Pharmacy Dpt, University Hospitals Leuven
Jan Verhaegen, MD PhD
Role: STUDY_CHAIR
Medical Diagnostic Sciences, University Hospitals Leuven
Hans Prenen, MD PhD
Role: STUDY_CHAIR
Digestive ONcology, University Hosptials Leuven
Willy Peetermans, MD PhD
Role: STUDY_CHAIR
Internal Medicine, University Hospitals Leuven
Ludo Willems, PharmD PhD
Role: STUDY_CHAIR
Pharmacy Dpt., University Hosptials Leuven
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S54585
Identifier Type: -
Identifier Source: org_study_id